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Lung Cancer Screening Using Multi-Slice Thin-Section
Computed Tomography and Autofluorescence
Bronchoscopy
Annette M. McWilliams, MD,* John R. Mayo, MD,† Myeong Im Ahn, MD,‡
Sharyn L. S. MacDonald, MD,† and Stephen C. Lam, MD*
Background: Thoracic computed tomography (CT) for lung cancer
screening is sensitive for the detection of early peripheral lung
cancer but is not sensitive for detecting central preinvasive and
microinvasive cancer. Our hypothesis is that the use of a two-step
strategy, using a sputum biomarker, may increase the detection rate
of lung cancer by identifying individuals at highest risk.
Methods: We completed a pilot study of 561 volunteer current or
former smokers 50 years of age or older, with a smoking history of
more than or equal to 30 pack years. All subjects received induced
sputum examination and low-dose thoracic CT scan and were
offered autofluorescence bronchoscopy.
Results: CT detected 2408 pulmonary nodules, 80% of which were
less than or equal to 4 mm in diameter. During 2-year follow-up,
95% of these nodules were stable or resolved, with only 4% showing
growth at any time. A total of 28 cancers were detected in 22
subjects: 21 by CT scan and seven by autofluorescence bronchos-
copy. Overall, 0.9% nodules were malignant, but growth on more
than or equal to two CT scans increased the malignancy rate to 75%.
The mean diameter of malignant nodules on detection was 12.8 mm
(range, 3 to 36.4 mm). However, 18% of malignant nodules were
less than or equal to 4 mm in diameter when first seen.
Conclusions: Multi-detector row CT scanners found multiple small
nodules in most subjects screened, but most were stable over the
2-year follow-up. Persistent interval growth increases the probability
of malignancy from less than 1% to 75%. One quarter of detected
cancers were CT occult and only seen with autofluorescence bron-
choscopy. Prescreening using a sputum biomarker improved the
detection rate of lung cancer from 3 to 5%.
KeyWords: Lung neoplasms, Tomography, X-ray computed, Bron-
choscopy, Diagnostic imaging, Cytology.
(J Thorac Oncol. 2006;1: 61–68)
The use of low-dose thoracic computed tomography(CT) for the early detection of lung cancer is being
evaluated in multiple centers around the world.1–11 Long-
term mortality outcome studies are being performed in
North America and Europe (CA Van Iersel et al., unpub-
lished data presented at the 11th International Conference
on Screening for Lung Cancer, Rome, Italy, October 15-
17, 2004).12 However, most of these studies only screen
with thoracic CT and do not evaluate the central airways or
use biomarkers to select the population of smokers who are
most at risk. Lung cancers found in screening studies only
using CT are predominantly adenocarcinoma, detected at a
rate of 0.4 to 2.7%.1–11
There is increasing interest in the use of biomarkers to
provide a selection mechanism for lung cancer screening
programs. The cumulative lifetime risk for the development
of lung cancer in male current smokers is only 16%, and in
female current smokers, it is less than 10%.13 The use of
multi-detector thoracic CT scans for screening is associated
with the detection of multiple small non-calcified pulmonary
nodules that require observation for 24 months.8,14 The use of
biomarkers may help to select individuals who are at risk of
developing lung cancer, thereby reducing the need for initial
screening and the associated second-line investigation and
follow-up of benign noncalcified lung nodules. This would
hopefully improve the positive predictive value of nodule
detection and, subsequently, the cost-effectiveness of a
screening program, as the population screened would have a
higher prevalence of disease.
We have reported the baseline results from our early
lung cancer detection program at the British Columbia Can-
cer Agency.14 In this study, we used a combination of
automated quantitative cytometry (AQC) of induced sputum,
autofluorescence bronchoscopy, and low-dose thoracic CT
scan in a population of high-risk current and former smokers.
We hypothesized that if we use a sputum biomarker such as
AQC of sputum cells as the first screening step, we could
identify individuals at highest risk to improve the lung cancer
detection rate on subsequent investigation with CT and
autofluorescence bronchoscopy. We now report the results of
a 2-year follow-up of this screened cohort and the results of
our experience with multi-detector row CT scans.
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METHODS
The methodology has been described in detail in the
publication and the online repository of the baseline results.14
Study Subjects
Low-dose spiral thoracic CT scan was added to the
early lung cancer detection program at the British Columbia
Cancer Agency in April 2000 as a sub-contract of a National
Cancer Institute-sponsored chemoprevention trial (N01-CN-
85188). Volunteer current and former smokers aged 50 to 74
years with a smoking history of more than or equal to 30 pack
years were recruited from the community. After an interview
and questionnaire, a sputum sample was obtained using
inhalation of nebulized 3% hypertonic saline and high-fre-
quency chest wall oscillations for 12 minutes with a ThAI-
Rapy Vest (Hill-Rom, St. Paul, MN). The sputum was eval-
uated using an automated high-resolution image cytometer
(Cyto-Savant; Perceptronix Medical Inc., Vancouver, BC,
Canada). Sputum atypia was defined as the presence of at
least five epithelial cells that had a DNA index greater than
1.2. A low-dose thoracic CT scan was booked at the time of
the interview and sputum collection. Subjects were offered an
autofluorescence bronchoscopy using the LIFE-Lung device
(Xillix Technologies Corp., Richmond, BC, Canada).
Approval was obtained from the Clinical Research
Ethics Board of the University of British Columbia and the
scientific review committee of the British Columbia Cancer
Agency. Written informed consent was obtained from all
participants.
Thoracic CT Scan
Baseline screening studies were performed at low dose,
with follow-up examinations obtained using the standard
diagnostic radiation dose used in our institution. CT scans
between June 1, 2000 and August 30, 2001 were performed
on a single-detector row GE CTi scanner (General Electric
Medical Systems, Wisconsin) using 7-mm collimation, 120-
kVp, 1-second scan time, and pitch of 1.0 and either 40 mA
(baseline scan) or 200 mA (follow-up scan). Contiguous
7-mm collimation images were reconstructed using the stan-
dard (standard) and high spatial frequency (bone) algorithms.
After September 1, 2001, scans were performed using either
a four-detector row (GE QXi Lightspeed Plus) or eight-
detector row (GE QXi Lightspeed Ultra) CT scanner. To
make data acquisition uniform between these two machines,
both were configured in four-detector row mode using
1.25-mm detector aperture, 120-kVp, 0.5-second rotation
time, pitch of 1.5, and either 80 mA (baseline scan) or 320
mA (follow-up scan). Images were reconstructed at a slice
width of 1.25 mm at 1.25-mm spacings using both the
standard (standard) and high spatial frequency (bone) algo-
rithms. After February 13, 2003, CT scans were performed
using a 16-detector row CT scanner (Siemens Sensation
Somatom 16; Siemens AG, Medical Solutions, Erlangen,
Germany). Images were acquired using a 0.75-mm detector
aperture, 120-kVp, 0.5-second rotation time, pitch 1.25, and
80 mA (baseline screen scan) or 200 mA (follow-up scan).
Images were reconstructed at 1-mm slice width at 1-mm
spacing using the standard (B35f) and high spatial frequency
(B60f) reconstruction algorithms.
An abnormal CT was defined by the presence of at least
one non-calcified pulmonary nodule or area of non-solid or
part-solid density. A nodule was considered benign if it showed
benign calcification pattern (central, diffuse, laminated, pop-
corn). Follow-up was arranged in subjects with an abnormal CT
result. Subjects with a normal baseline CT scan were not offered
CT scan follow-up. Lesions 4 mm or smaller were re-examined
at 6, 12, and 24 months. Lesions 4 to 9 mm were re-examined
at 3,6,12, and 24 months. Abnormalities 10 mm or larger were
assessed on an individual basis for further investigation. The site
and size of all detected lesions were recorded in an electronic
database using Paradox for Windows software (version 7) (File-
Maker, Santa Clara, California). Many nodules that were de-
tected on follow-up examinations could, in retrospect, be seen
on previous baseline low-dose or follow-up examinations. These
nodules were identified in the database as retrospectively iden-
tified nodules.
Growth of a solid nodule was defined as an increase in
either maximal long axis or short axis diameter of at least 1
mm. The same size criteria were also used for non-solid
opacities, but, in addition, a change in density of the non-
solid lesion without a change in maximal long axis diameter
was also defined as growth. If these changes were reported in
any visible lesion, then a repeat scan was arranged in 3
months. Subjects were referred for surgical resection if there
was persistent growth of a pulmonary nodule or change in
density or size of a non-solid opacity on sequential CT scans.
RESULTS
A total of 561 subjects were enrolled in the study. All
subjects with an abnormal baseline CT scan (259 of 561)
were followed with serial CT scans as part of the study
protocol until all nodules or non-solid opacities had been
observed to be stable in size for at least 24 months, were seen
to be benign (calcified), or had resolved. Subjects with a
normal baseline CT were not followed unless they were part
of the chemoprevention study. The outcome of subjects who
did not receive follow-up CT examinations was tracked
through the Cancer Registry of British Columbia. By law,
pathology laboratories in the province of British Columbia
are required to report all newly diagnosed cancers to this
Registry. Through January 30, 2005, there were no cases of
lung cancer in this cohort except those found by this screen-
ing program.
Pulmonary Nodules
A total of 2408 pulmonary lesions were detected. Of
these lesions, 92% were solid nodules (2219 of 2408), and
only 8% were non-solid or part-solid opacities (189 of 2408).
Sixty percent (1456 of 2408) of lesions were visible on the
baseline CT scan (prevalence lesions), and 40% (952 of
2408) appeared during follow-up (incidence lesions). Sixty-
two percent (1492 of 2408) of all lesions (prevalence and
incidence) were detected in retrospect on follow-up exami-
nations, being visible on earlier scans but not identified by the
readers. Subjects with a normal baseline scan did not have
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follow-up CT scans, and it is likely that some nodules may
have been missed in this group.
During 2 years of observation, 95% (2294 of 2408) of
lesions remained stable, resolved, or were seen to be benign.
In follow-up, 4% of lesions (105 of 2408) showed growth on
one CT scan (Table 1). Further CT scan follow-up or inves-
tigation of these growing lesions revealed that 12% (13 of
105) were malignant. If the lesions were seen to persistently
enlarge on two or more consecutive CT scans, then 75% (12
of 16) were malignant.
By maximal long axis diameter, most detected lesions
were small: 78% (1882 of 2408) were 4 mm or smaller, 19%
(450 of 2408) were 4 to10 mm, and 3% (76 of 2408) were 10
mm or larger. Overall, 0.9% (22 of 2408) of all lesions were
found to be malignant, including 21 primary lung cancers and
one metastatic lymph node (Table 1). In each of these size
groups, 0.2% (4 of 1882) of nodules 4 mm or smaller, 1% (5
of 450) of nodules 4 to 10 mm, and 17% (13 of 76) of nodules
10 mm or larger were found to be malignant. The mean size
of malignant nodules when first visible was 12.8 mm in
diameter (range, 3 to 36.4 mm). However, 18% (4 of 22) of
malignant lesions were less than 4 mm, and 36% (8 of 22)
were less than 8 mm in diameter when first visible. Detect-
able growth (increase of 1 mm in maximal long axis diame-
ter) was seen in 75% (6 of 8) of lesions less than 8 mm in
diameter within 6 months of detection.
CT-Detected Lung Cancers
A total of 21 primary lung cancers in 11 women and 7
men (mean age 63 years; range, 53 to 77 years) were detected
by CT scan (Tables 2, 3, and 4). At enrollment, 12 were
current smokers and six were former smokers. There were 16
prevalence and five incidence cancers. Of these 21 cancers,
10 were reported in our baseline results.15 The histological
subtypes of CT-detected lung cancers included 86% (18 of
21) non–small-cell lung carcinoma (NSCLC), 9.5% (2 of 21)
small-cell carcinoma, and 4.8% (1 of 21) mixed small- and
large-cell carcinoma. Most NSCLC (14 of 18) were adeno-
carcinoma. Overall, 78% (14 of 18) of the NSCLC was stage
I.
Computer software that enabled the performance of
volumetric analysis of growing nodules recently became
available at Vancouver General Hospital using the Leonardo
workstation and LungCare Volumetric Program (Siemens
AG, Medical Solutions, Erlangen, Germany). This software
was then used to retrospectively evaluate the growing malig-
nant nodules detected on CT follow-up and to calculate
volume doubling times of these lesions (Tables 3 and 4).
Only one lesion was unable to be evaluated with the software
(from subject 9) (Table 3). Tumor volume doubling times
were seen to vary widely from 25 days for a prevalence
adenocarcinoma (subject 11) (Table 3) to 900 days for an
incidence squamous cell carcinoma (subject 11) (Table 4).
Prevalence Cancers
Most of the 16 prevalence cancers were NSCLC (15 of
16), and there was one case of mixed small- and large-cell
carcinoma. Of the NSCLC, 80% (12 of 15) was adenocarci-
noma.
Half of the prevalence cancers (8 of 16) were large
solid lesions (mean maximal long axis diameter 18 mm;
range, 10 to 25 mm) that were detected on the baseline
screening CT scan and received immediate investigation and
resection (Table 2). All cases were treated surgically, and
63% (5 of 8) were stage I. Two subjects (7 and 8) had
additional chemoradiation.
The remainder of the CT-detected prevalence cancers
(8 of 16) were diagnosed after detection of growth or a
change in density during follow-up, and 88% (7 of 8) were
stage 1 (Table 3). The mean diameter when first seen was 9.7
mm; at surgical referral it was 14 mm; and at surgery it was
14.7 mm. There were significant delays in the time to surgery
for these lesions with a mean of 25 months (range, 8 to 42
months) from baseline. There were multiple factors that
contributed to this prolonged time to surgery. First, some
lesions were only detected in retrospect on a follow-up scan.
(Figure 1A and B ). Other lesions were stable for long periods
of time before showing growth or a change in appearance
(Figure 2 A and B ). In addition, some subjects delayed
surgery or investigations for personal reasons despite strong
recommendations from the investigators. All of the lesions
except one were surgically resected (Table 3). The non-
resected lesion was biopsied.
Incidence Cancers
A total of five incidence cancers were detected by CT
scan, including two adenocarcinoma, one squamous cell car-
cinoma, and two small-cell carcinoma (Table 4). Two of
these were second primary cancers in two subjects (subjects
4 and 11) who had previously had a prevalence cancer
resected as part of the study.
The two incidence adenocarcinomas were detected in
two current smokers (subjects 16 and 17) (Table 4). Both
lesions were visible in retrospect on the 3-month follow-up
CT scan but were not visible on the low-dose baseline scan.
Both follow-up and baseline scans for each patient were
performed using the same section collimation, but the fol-
low-up scans were performed using a higher tube current.
The incidence of stage IA squamous cell carcinoma was
found in a former smoker who had a previous prevalence
stage IA adenocarcinoma detected on CT and was undergoing
continued follow-up of other nodules (subject 11). This
patient developed a new 3-mm nodule during postoperative
follow-up that was initially stable for 12 months and then
enlarged. All three incidences of NSCLC were surgically
resected.
TABLE 1. Pulmonary Nodule Behavior
Seen at New on Total
baseline follow-up
No. of lesions 1456 952 2408
Resected immediately 8 0 8
Stable/improved 1380 915 2295
Growth 68 37 105
Total malignant 16 6 22
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Two small-cell carcinomas were detected on CT scan
follow-up in two current smokers (Table 4). The first oc-
curred in a subject with a previous prevalence squamous cell
carcinoma diagnosed on the baseline CT scan undergoing
continued follow-up of other nodules (subject 4). A 36-mm
de novo mass was detected that had not been present on a CT
scan performed 12 months earlier. The second small-cell
cancer occurred in subject 18 during follow-up. This subject
developed a number of new nodules and areas of consolida-
tion seen at the routine 24-month scan after the occurrence of
a respiratory tract infection. With further observation, most of
the new findings resolved except for a 7-mm nodule that
persisted and then enlarged to 10 mm.
Bronchoscopically Detected Lung Cancers
A total of seven squamous cell carcinomas in four
subjects were found using autofluorescence bronchoscopy
(Table 5). These lesions were radiologically occult even on
retrospective review of the thoracic CT scan by the study
radiologist (JM). Half of the subjects had other pulmonary
nodules on their baseline thoracic CT scan. The subjects
included one woman and three men, and the mean age was
59.6 years. At enrolment, two were current smokers and two
were former smokers. There were four prevalence and three
incidence cancers. The three incidence cancers were detected
on bronchoscopic follow-up in one subject with an occult
TABLE 2. CT Scan-Detected Lung Cancers Diagnosed at Baseline Screen
Subject Cell type CT appearance Stage
Size first visible
(mm)
1 Poorly differentiated carcinoma Solid IA 10
2 Adenocarcinoma Solid IA 12
3 Adenocarcinoma Solid IB 18
4 Squamous cell carcinoma Solid IB 20
5 Adenocarcinoma Solid IB 25
6 Adenocarcinoma Solid IIA 15
7 Adenocarcinoma Solid IIIA 23
8 Mixed small/large-cell carcinoma Solid IIB 20
CT, computed tomography.
TABLE 3. CT-Detected Prevalence Lung Cancers Diagnosed on CT Follow-up
Subject Cell type
CT
appearance Stage
Size first
visible (mm)
Size at
surgical
referral (mm)
Size in
resected
specimen
(mm)
Time to surgery
from baseline
(months)
Tumor volume
doubling time
(days)
9 Adenocarcinoma Solid IA 6 7 10 26 264
9 Adenocarcinoma Non-solid IA 15 24 25 26 -
10 Adenocarcinoma Solid IA 10 12 16 36 648
11 Adenocarcinoma Non-solid IA 9 11 11 8 25
12 Adenocarcinoma Non-solid IA 16 22 15 29 434
13 Adenocarcinoma Solid IIIA 11 13 NA 20 795
14 Squamous cell carcinoma Solid IA 3 15 17 16 78
15 Adenocarcinoma Non-solid IA 7.5 11 9 42 817
NA, not applicable as lesion not resected; CT, computed tomography.
TABLE 4. CT Scan-Detected Incidence Cancers
Subject Cell type
CT
appearance Stage
Size first
visible (mm)
Size at
surgical referral
(mm)
Size in
resected
specimen (mm)
Time to surgery
from first visible
(months)
Tumor volume
doubling time
(days)
11 Squamous cell carcinoma Solid IA 3 13 12 18 900
16 Adenocarcinoma Solid IIA 3 9 8 15 85
17 Adenocarcinoma Solid IA 7 11 8 15 344
18 Small-cell carcinoma Solid Limited 7 10 15 6 84
4 Small-cell carcinoma Solid Limited 36 NA NA NA 48
NA, not applicable as lesion not resected; CT, computed tomography.
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squamous cell carcinoma detected on the baseline screening
bronchoscopy. Surgical resection was performed in two sub-
jects, and endoscopic treatment with electrocautery/cryother-
apy was used in two subjects. The one subject with multiple
metachronous lesions had a lobectomy for treatment of the
prevalence cancer, endoscopic treatment of the incidence
cancers, and finally a completion left pneumonectomy be-
cause of persistent disease.
False-Positive Surgeries
In addition to the 19 surgeries for lung cancer resection,
seven subjects underwent surgery for enlarging pulmonary
nodules that were nonmalignant. Most of these nodules (6 of
7) were detected at the baseline thoracic CT scan and showed
growth on follow-up. One lesion was new on follow-up and
showed rapid growth. Six subjects underwent video-assisted
thoracoscopic surgery with wedge resection, and one subject
required a lobectomy. The final pathology was lymph node,2
necrotizing granuloma,1 cryptococcoma,1 hamartoma,2 and
inflammatory tissue.1 Therefore, of the 26 subjects who
underwent video-assisted thoracoscopic resection or standard
lobectomies, seven resections (27%) were for a benign con-
dition. Of all the subjects screened, 1% underwent unneces-
sary surgery (7 of 561).
Sputum Results
Of the 561 screened subjects in the cohort, 423 had
sputum atypia and 138 had normal sputum by AQC at baseline.
FIGURE 1. A, 15-mm nodule in left upper lobe seen on 12
month follow-up scan. B, 3-mm nodule in left upper lobe
retrospectively seen on baseline scan.
FIGURE 2. A, 8-mm nodule in right upper lobe on baseline
scan. B, Previously stable nodule in right upper lobe looks
larger on final 24-month follow-up scan.
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All of the subjects with central CT occult squamous cell carci-
noma had sputum atypia. Of the subjects with a peripheral
carcinoma, 15 of 18 (83%) had baseline sputum atypia. How-
ever, two subjects with normal baseline cytometry developed
atypia on repeat testing as the cancers grew on CT scan follow-
up, resulting in 17 of 18 (94%) with sputum atypia at the time of
resection. Overall, 95% of subjects (21 of 22) with a detected
cancer had sputum atypia on quantitative sputum cytometry.
Lung Cancer Detection
The use of a sputum biomarker increased the detection
of lung cancer in this cohort. If CT scan alone had been used
for these subjects, the detection rate would be 3% (18 of 561).
By using a sputum biomarker as the first screening step and
performing autofluorescence bronchoscopy and CT scan only
in subjects with abnormal sputum cytometry, the detection
rate would be 5% (21 of 423) (Table 6).
DISCUSSION
Only a small proportion of lifelong smokers develop
lung cancer; however, lung cancer remains the major cause of
cancer death.15 This is largely a result of the presentation of
most patients with inoperable disease. Compared with screening
using the chest radiograph, CT screening detects lung cancers at
an earlier stage and smaller size. The impact on disease-specific
mortality, however, remains to be determined.1–11,14 Given the
high prevalence of CT-detected benign nodules in smokers,
improved selection of subjects for screening is crucial to develop
cost-effective and efficient screening programs.
The definition of a high-risk patient is undergoing
change, and the traditional use of demographic and smoking
data alone seems to be inadequate. Research regarding a
patient’s cancer susceptibility suggests that some individuals
have reduced DNA repair mechanisms, which may lead to
increased accumulation of genetic mutations and increased
risk of cancer development after exposure to cigarette
smoke.16 Further work is underway to identify DNA repair
gene polymorphisms that will predict a poor DNA repair
capacity.16,17 Interestingly, recent research in nonsmoking
Chinese patients with lung cancer has revealed an association
of lung cancer with polymorphisms of GSTT1 and CYP1A1
genotypes, which suggests that changes in phase I and II
enzymes and the activation and detoxification of carcinogens
may play a role in lung cancer risk.18,19 Ultimately, determi-
nation of a high-risk patient’s genotype would be useful in
both primary and secondary prevention strategies and in the
selection of subjects to be screened for lung cancer.
The use of biomarkers to detect patients with an early
lung cancer is also needed to identify those who require
second-line investigation for cancer localization. Detection of
a circulating serum DNA marker such as hTERT has shown
promising results in early case-control studies.20 Detection of
other abnormalities in serum and sputum, such as microsat-
ellite alterations, methylation of the promoter of various
tumor suppressor genes, and specific oncogene mutations are
also being investigated.21–27 In addition to these genomic
techniques, imaging of sputum cells with methods such as
quantitative image cytometry and detection of malignancy-
associated changes is undergoing investigation.14 An exciting
recent development is the use of exhaled breath condensate to
detect lung cancer with volatile organic compounds or mo-
lecular markers.28,29 Phillips et al.28 reported a sensitivity of
90% and specificity of 83% for detection of lung cancer
measuring oxidative stress products such as alkanes and
monomethylated alkanes in exhaled breath. It may have a role
in screening because it can be incorporated as part of spirom-
etry testing if the technology can be simplified and the
chemicals separating patients with cancer from those without
cancer are better defined. The potential of a biomarker as the
first step in screening is that if we can identify individuals at
highest risk of lung cancer, the positive predictive value of
more selectively applied spiral CT and autofluorescence
bronchoscopy will improve significantly.
The best method of investigation for subjects who are
identified as being at highest risk is unknown. Most published
screening studies use spiral CT scans with slice widths of 5 to
10 mm and do not evaluate the central airways. Thoracic CT
scans detect multiple small pulmonary nodules, and the
clinical significance and best observation protocol for these
lesions are still uncertain. In this pilot study, thoracic CT
scans were initially performed with a 7-mm single-detector
TABLE 5. LIFE-Detected Lung Cancers
Subject Cell Type Presentation Stage Treatment
19 Squamous cell carcinoma Prevalence 0 Lobectomy
20 Squamous cell carcinoma Prevalence 0 Electrocautery
21 Squamous cell carcinoma Prevalence 0 Electrocautery
22 Squamous cell carcinoma Prevalence IA Lobectomy
22 Squamous cell carcinoma Incidence 0 Cryotherapy
22 Squamous cell carcinoma Incidence 0 Electrocautery
22 Squamous cell carcinoma Incidence 0 Electrocautery/photodynamic therapy/surgery
LIFE, XXX.
TABLE 6. Lung Cancer Detection
Overall AQC atypia
Number of subjects 561 423
CT scan alone 18 17
CT scan and LIFE 22 21
AQC, automated quantitative cytometry; CT, computed tomography; LIFE, XXX.
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row scanner and then with 4-, 8-, and 16-multi-detector row
CT scanners. We have shown that these technical changes
substantially increase the detection of peripheral lung nod-
ules, with nearly 80% being 4 mm or smaller in diameter.
Long-term follow-up of more than 2000 of these lesions have
shown that most are stable or benign over time. However, in
this study, the most important indicator of malignant potential
was growth on two or more sequential CT scans, in which the
risk of malignancy was shown to increase from less than 1%
to 75%. In this study, cancers detected on CT scan follow-up
because of growth or change in CT appearance were of a
smaller size than those detected at the baseline scan, and there
was a greater proportion of stage I cancers (88% versus 63%).
This has also been previously documented by Henschke et
al.2 An important finding that has not, to our knowledge, been
previously reported, is that 18% of malignant nodules were
smaller than 4 mm when first visible, which indicates that
small pulmonary nodules cannot be ignored. Many of these
small lesions had detectable growth within 6 months of
detection, indicating that close follow-up is required.
Some important problems that we have found in our
study include significant delay to resection in some cases and
a significant false-positive surgical rate. When considering a
community-based screening program, it is important to con-
sider these factors and to improve our interventional algo-
rithms and techniques to resect cancers at the earliest possible
time and reduce unnecessary surgery. Some of these factors
were related to delays in attending CT follow-up or interven-
tion by the subjects, and this is always a clinical challenge for
the physician. Another factor is that some lesions were only
seen in retrospect, which is a common phenomenon in CT
scan screening.2,30,31 In our study, we found that 62% of
pulmonary lesions were detected in retrospect, and this is
most likely a result of using higher tube current and thinner
slice width in the follow-up scans, which resulted in im-
proved observer detection. New technologies that assist the
radiologist in both the automated detection of pulmonary
nodules and the early detection of growth will be extremely
important in a lung cancer screening program to identify
potential malignant nodules and enable earlier resection.32,33
Interestingly, the biological behavior of some of these pe-
ripheral lesions resulted in delay to resection. Some lesions
seemed to be stable for long periods of time during CT scan
follow-up and only showed change after 2 years of observa-
tion. The behavior and biology of peripheral adenocarcinoma
has stimulated much recent interest, and research is revealing
significant differences in biology, pathology, and prognosis in
different subtypes of adenocarcinoma.10,34–42
To reduce false-positive surgical rates, improved pre-
operative diagnostic techniques are required. However, in-
vestigation of small peripheral lesions less than 10 mm in size
is limited by both technical skill in fine needle aspiration and
limitation of diagnostic yields for bronchoscopy, positron
emission tomography scan, and contrast CT scan. These types
of investigations are not usually helpful with these small
lesions.43–48 Novel localization techniques using electromag-
netic navigation to aid the early diagnosis of suspiciously
behaving peripheral pulmonary lesions and other transtho-
racic techniques that assist thoracoscopic resection of small
growing peripheral lesions look promising.49,50
Evaluation of the central airways is important as re-
vealed in our study in which 25% of detected cancers were
radiologically occult, emphasizing the limitation of CT scan
in detecting central carcinoma in situ or microinvasive car-
cinoma. We found that 70% of squamous cell cancers in our
cohort were CT occult. This has important implications when
considering the population to be screened. In North America,
squamous cell carcinoma accounts for approximately 37% of
the lung cancers in men and 20% of the lung cancers in
women. However, in Europe, a higher proportion of lung
cancers are squamous cell carcinoma: approximately 47%
and 27% of the lung cancers in men and women, respective-
ly.15 Thus, if squamous cell carcinoma remains a significant
contributor to lung cancer in a screened population, then it is
important to evaluate the central airways using a more sen-
sitive technique such as autofluorescence bronchoscopy.
The use of a sputum biomarker (AQC) in combination
with autofluorescence bronchoscopy and CT scan in our
cohort increased the detection rate of lung cancer from 3 to
5%. The reported detection rate of lung cancer using CT scan
alone varies between 0.4 and 2.7 %.1–11 Our detection rate
using CT scan alone (3%) is similar to these rates. The longer
term follow-up of this cohort confirms the findings from the
early baseline report that more than 90% of lung cancers
detected were found in subjects with sputum atypia by auto-
mated quantitative cytometry.14
The future of cost-effective targeted lung cancer
screening relies on the use of biomarkers to identify highest
risk subjects and prioritization of cancer localization tech-
niques depending on the patient’s risk profile. The develop-
ment of new technologies integrated into the screening pro-
cess will result in earlier detection, diagnosis, and treatment
of early central and peripheral lung cancers.
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